GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced that they have entered into an exclusive worldwide collaboration agreement for the investigational drug retigabine, a first in class neuronal potassium channel opener for treatment of adult epilepsy patients with refractory partial onset seizures.
Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
ADAGIO trial results show Azilect® slows progression of Parkinson's disease
- Details
- Category: Lundbeck
Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain. The ADAGIO study showed that Parkinson's disease patients who took Azilect® (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated therapy with the drug nine months later.
Brings complementary capabilities in India to address patient populations most at risk
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&D) organization dedicated to reducing the burden of malaria, announced a new collaboration with India's Advinus Therapeutics Ltd.
Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc.
- Details
- Category: Financial
Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the outstanding shares of Alpharma for $33.00 per share in cash. Alpharma said that proposal was identical in all material respects to two prior proposals made privately by King to the company.
King Proposes Acquisition of Alpharma for $33 Per Share in Cash
- Details
- Category: Financial
King Pharmaceuticals, Inc. (NYSE: KG) announced that it has submitted to the Board of Directors of Alpharma Inc. (NYSE: ALO) a proposal to acquire all of the outstanding shares of common stock of Alpharma for $33.00 per share in cash. The proposal is not conditioned on financing.
New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar® (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo-controlled study is evaluating Nexavar as an adjuvant therapy for patients with hepatocellular carcinoma (HCC), or primary liver cancer.
More Pharma News ...
- Novo Nordisk joins the Call to Action for gender equality
- DAIICHI SANKYO continues its expansion in Germany and Europe
- Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance
- Nycomed - strong results in second quarter 2008
- Divestment of four Roche pharmaceutical products to Meda
- AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR®
- Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million